WallStSmart

Merck & Company Inc (MRK)vsScworx Corp (WORX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 2285416% more annual revenue ($65.77B vs $2.88M). MRK leads profitability with a 13.6% profit margin vs -154.4%. MRK earns a higher WallStSmart Score of 50/100 (D+).

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.30

WORX

Hold

37

out of 100

Grade: F

Growth: 4.0Profit: 2.0Value: 5.0Quality: 5.5
Piotroski: 4/9Altman Z: -5.94
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-49.3%)

Margin of Safety

-49.3%

Fair Value

$80.88

Current Price

$120.79

$39.91 premium

UndervaluedFair: $80.88Overvalued

Intrinsic value data unavailable for WORX.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$285.64B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

WORX2 strengths · Avg: 10.0/10
Price/BookValuation
0.7x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0010/10

Conservative balance sheet, low leverage

Areas to Watch

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
32.6x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

WORX4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$426,6503/10

Smaller company, higher risk/reward

Return on EquityProfitability
-74.1%2/10

ROE of -74.1% — below average capital efficiency

Free Cash FlowQuality
$-139,7002/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : WORX

The strongest argument for WORX centers on Price/Book, Debt/Equity. Revenue growth of 13.8% demonstrates continued momentum.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Bear Case : WORX

The primary concerns for WORX are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

MRK profiles as a value stock while WORX is a turnaround play — different risk/reward profiles.

WORX carries more volatility with a beta of 1.63 — expect wider price swings.

WORX is growing revenue faster at 13.8% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (50/100 vs 37/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Scworx Corp

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

Scworx Corp (WORX) stands at the forefront of healthcare data solutions, dedicated to optimizing clinical data management for healthcare providers and stakeholders. Utilizing cutting-edge technology, the company enhances operational efficiency and bolsters the quality of care through robust analytics, empowering institutions to make informed, data-driven decisions. With a strategic focus on scalability and innovation, Scworx is well-positioned to meet the growing demand for data-centric solutions in the healthcare sector, thereby improving patient outcomes and enabling effective cost management. This commitment to transforming healthcare delivery solidifies Scworx's critical role in the rapidly evolving healthcare landscape.

Visit Website →

Want to dig deeper into these stocks?